1.86 -0.11 (-5.58%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 2.42 | 1-year : | 2.73 |
Resists | First : | 2.07 | Second : | 2.33 |
Pivot price | 2 | |||
Supports | First : | 1.63 | Second : | 1.36 |
MAs | MA(5) : | 2.03 | MA(20) : | 1.97 |
MA(100) : | 1.59 | MA(250) : | 4.7 | |
MACD | MACD : | 0 | Signal : | 0.1 |
%K %D | K(14,3) : | 48 | D(3) : | 56.3 |
RSI | RSI(14): 48.3 | |||
52-week | High : | 26.39 | Low : | 1.08 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SONN ] has closed above bottom band by 31.0%. Bollinger Bands are 29.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 2.03 - 2.05 | 2.05 - 2.06 |
Low: | 1.87 - 1.89 | 1.89 - 1.91 |
Close: | 2 - 2.03 | 2.03 - 2.05 |
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
Tue, 19 Mar 2024
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy ... - Kansas City Star
Tue, 19 Mar 2024
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy ... - Chronicle-Tribune
Tue, 12 Mar 2024
Sonnet BioTherapeutics Holdings, Inc. (SONN) Down 10.63% in Premarket Trading - InvestorsObserver
Mon, 11 Mar 2024
Where Will Sonnet BioTherapeutics Holdings, Inc. (SONN) Stock Go Next After It Is Up 1.06% in a Week? - InvestorsObserver
Mon, 11 Mar 2024
Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in ... - Yahoo Finance
Thu, 29 Feb 2024
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy ... - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 3 (M) |
Held by Insiders | 2.71e+006 (%) |
Held by Institutions | 11.7 (%) |
Shares Short | 167 (K) |
Shares Short P.Month | 0 (K) |
EPS | -1.445e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -6 % |
Return on Assets (ttm) | 866 % |
Return on Equity (ttm) | -175.9 % |
Qtrly Rev. Growth | 129180 % |
Gross Profit (p.s.) | -45.05 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -0.9 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -19 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | 2.48 |
Dividend | 0 |
Forward Dividend | 254070 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |